| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing1@energy-chemical.com |
| Products Intro: |
Product Name:Olopatadine-d3 Hydrochloride
CAS:1331635-21-2
Purity:NULL Package:10mg;1mg Remarks:NULL
|
| Company Name: |
ChemeGen 中国
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:Olopatadine-d3 hydrochloride
CAS:1331635-21-2
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Olopatadine-d3 Hydrochloride
CAS:1331635-21-2
Purity:>95% Package:1mg
|
| Company Name: |
Nanjing Shizhou Biology Technology Co.,Ltd
|
| Tel: |
17301488900 |
| Email: |
judy.xia@synzest.com |
| Products Intro: |
Product Name:Olopatadine-d3 Hydrochloride
CAS:1331635-21-2
Purity:99% HPLC Package:1MG;5MG:10MG
|
|
| | HVRLZEKDTUEKQH-NEGCSKJWSA-N Basic information |
| Product Name: | HVRLZEKDTUEKQH-NEGCSKJWSA-N | | Synonyms: | HVRLZEKDTUEKQH-NEGCSKJWSA-N;[2H3]- Olopatadine Hydrochloride;2-[(11Z)-11-[3-[methyl(trideuteriomethyl)amino]propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid | | CAS: | 1331635-21-2 | | MF: | C21H21ClD3NO3 | | MW: | 376.891645334 | | EINECS: | | | Product Categories: | | | Mol File: | 1331635-21-2.mol |  |
| | HVRLZEKDTUEKQH-NEGCSKJWSA-N Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Methanol: Slightly soluble, | | form | A solid | | Water Solubility | Water: Slightly soluble |
| | HVRLZEKDTUEKQH-NEGCSKJWSA-N Usage And Synthesis |
| Uses | Labelled Olopatadine. Dual acting histamine H1-receptor antagonist and mast cell stabilizer. Antiallergic; antihistaminic. | | Biological Activity | Olopatadine-d3 is intended for use as an internal standard for the quantification of olopatadine by GC- or LC-MS. Olopatadine is a histamine H1 receptor antagonist (Ki =41 nM).1 It is 1,059- and 4,177-fold selective for histamine H1 over H2 and H3 receptors, respectively. Olopatadine inhibits histamine-induced phosphoinositide turnover in isolated human conjunctival epithelial cells, isolated human corneal fibroblasts, and human trabecular meshwork (TM3) cells (IC50s = 9.5, 19, and 39.9 nM, respectively). In vivo, olopatadine inhibits passive cutaneous anaphylaxis in rats (ED50 = 49 μg/kg) and IgG1-mediated bronchoconstriction in ovalbumin-sensitized guinea pigs (ED50 = 30 μg/kg).2 Formulations containing olopatadine have been used in the treatment of allergic rhinitis and conjunctivitis, as well as in the treatment of itch in patients with well-controlled urticaria. | | References | 1.Sharif, N.A., Xu, S.X., and Yanni, J.M.Olopatadine (AL-4943A): Ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitisJ. Ocul. Pharmacol. Ther.12(4)401-407(1996)
2.Ohshima, E., Otaki, S., Sato, H., et al.Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivativesJ. Med. Chem.35(11)2074-2084(1992) |
| | HVRLZEKDTUEKQH-NEGCSKJWSA-N Preparation Products And Raw materials |
|